 |
PDBsum entry 1l8g
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hydrolase
|
 |
|
Title:
|
 |
Crystal structure of ptp1b complexed with 7-(1,1-dioxo-1h- benzo[d]isothiazol-3-yloxymethyl)-2-(oxalyl-amino)-4,7-dihydro-5h- thieno[2,3-c]pyran-3-carboxylic acid
|
|
Structure:
|
 |
Protein-tyrosine phosphatase, non-receptor type 1. Chain: a. Synonym: ptp1b, protein-tyrosine phosphatase 1b. Engineered: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Expressed in: escherichia coli. Expression_system_taxid: 562
|
|
Resolution:
|
 |
|
2.50Å
|
R-factor:
|
0.189
|
R-free:
|
0.270
|
|
|
Authors:
|
 |
L.F.Iversen,H.S.Andersen,K.B.Moller,O.H.Olsen,G.H.Peters,S.Branner, S.B.Mortensen,T.K.Hansen,J.Lau,Y.Ge,D.D.Holsworth,M.J.Newman, N.P.H.Moller
|
Key ref:
|
 |
L.F.Iversen
et al.
(2001).
Steric hindrance as a basis for structure-based design of selective inhibitors of protein-tyrosine phosphatases.
Biochemistry,
40,
14812-14820.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
20-Mar-02
|
Release date:
|
08-May-02
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
P18031
(PTN1_HUMAN) -
Tyrosine-protein phosphatase non-receptor type 1 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
435 a.a.
297 a.a.*
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
*
PDB and UniProt seqs differ
at 2 residue positions (black
crosses)
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.3.1.3.48
- protein-tyrosine-phosphatase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
O-phospho-L-tyrosyl-[protein] + H2O = L-tyrosyl-[protein] + phosphate
|
 |
 |
 |
 |
 |
O-phospho-L-tyrosyl-[protein]
|
+
|
H2O
|
=
|
L-tyrosyl-[protein]
|
+
|
phosphate
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Biochemistry
40:14812-14820
(2001)
|
|
PubMed id:
|
|
|
|
|
| |
|
Steric hindrance as a basis for structure-based design of selective inhibitors of protein-tyrosine phosphatases.
|
|
L.F.Iversen,
H.S.Andersen,
K.B.Møller,
O.H.Olsen,
G.H.Peters,
S.Branner,
S.B.Mortensen,
T.K.Hansen,
J.Lau,
Y.Ge,
D.D.Holsworth,
M.J.Newman,
N.P.Hundahl Møller.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Utilizing structure-based design, we have previously demonstrated that it is
possible to obtain selective inhibitors of protein-tyrosine phosphatase 1B
(PTP1B). A basic nitrogen was introduced into a general PTP inhibitor to form a
salt bridge to Asp48 in PTP1B and simultaneously cause repulsion in PTPs
containing an asparagine in the equivalent position [Iversen, L. F., et al.
(2000) J. Biol. Chem. 275, 10300-10307]. Further, we have recently demonstrated
that Gly259 in PTP1B forms the bottom of a gateway that allows easy access to
the active site for a broad range of substrates, while bulky residues in the
same position in other PTPs cause steric hindrance and reduced substrate
recognition capacity [Peters, G. H., et al. (2000) J. Biol. Chem. 275,
18201-18209]. The current study was undertaken to investigate the feasibility of
structure-based design, utilizing these differences in accessibility to the
active site among various PTPs. We show that a general, low-molecular weight PTP
inhibitor can be developed into a highly selective inhibitor for PTP1B and
TC-PTP by introducing a substituent, which is designed to address the region
around residues 258 and 259. Detailed enzyme kinetic analysis with a set of
wild-type and mutant PTPs, X-ray protein crystallography, and molecular modeling
studies confirmed that selectivity for PTP1B and TC-PTP was achieved due to
steric hindrance imposed by bulky position 259 residues in other PTPs.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
Y.Huang,
and
A.Dömling
(2011).
The Gewald multicomponent reaction.
|
| |
Mol Divers,
15,
3.
|
 |
|
|
|
|
 |
D.Vidović,
and
S.C.Schürer
(2009).
Knowledge-based characterization of similarity relationships in the human protein-tyrosine phosphatase family for rational inhibitor design.
|
| |
J Med Chem,
52,
6649-6659.
|
 |
|
|
|
|
 |
J.F.Wang,
K.Gong,
D.Q.Wei,
Y.X.Li,
and
K.C.Chou
(2009).
Molecular dynamics studies on the interactions of PTP1B with inhibitors: from the first phosphate-binding site to the second one.
|
| |
Protein Eng Des Sel,
22,
349-355.
|
 |
|
|
|
|
 |
K.Hellmuth,
S.Grosskopf,
C.T.Lum,
M.Würtele,
N.Röder,
J.P.von Kries,
M.Rosario,
J.Rademann,
and
W.Birchmeier
(2008).
Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking.
|
| |
Proc Natl Acad Sci U S A,
105,
7275-7280.
|
 |
|
|
|
|
 |
K.M.Picha,
S.S.Patel,
S.Mandiyan,
J.Koehn,
and
L.P.Wennogle
(2007).
The role of the C-terminal domain of protein tyrosine phosphatase-1B in phosphatase activity and substrate binding.
|
| |
J Biol Chem,
282,
2911-2917.
|
 |
|
|
|
|
 |
A.J.Barr,
J.E.Debreczeni,
J.Eswaran,
and
S.Knapp
(2006).
Crystal structure of human protein tyrosine phosphatase 14 (PTPN14) at 1.65-A resolution.
|
| |
Proteins,
63,
1132-1136.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.J.Barr,
and
S.Knapp
(2006).
MAPK-specific tyrosine phosphatases: new targets for drug discovery?
|
| |
Trends Pharmacol Sci,
27,
525-530.
|
 |
|
|
|
|
 |
D.Tolkatchev,
R.Shaykhutdinov,
P.Xu,
J.Plamondon,
D.C.Watson,
N.M.Young,
and
F.Ni
(2006).
Three-dimensional structure and ligand interactions of the low molecular weight protein tyrosine phosphatase from Campylobacter jejuni.
|
| |
Protein Sci,
15,
2381-2394.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
G.X.Liu,
J.Z.Tan,
C.Y.Niu,
J.H.Shen,
X.M.Luo,
X.Shen,
K.X.Chen,
and
H.L.Jiang
(2006).
Molecular dynamics simulations of interaction between protein-tyrosine phosphatase 1B and a bidentate inhibitor.
|
| |
Acta Pharmacol Sin,
27,
100-110.
|
 |
|
|
|
|
 |
J.Eswaran,
J.E.Debreczeni,
E.Longman,
A.J.Barr,
and
S.Knapp
(2006).
The crystal structure of human receptor protein tyrosine phosphatase kappa phosphatase domain 1.
|
| |
Protein Sci,
15,
1500-1505.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.Nayal,
and
B.Honig
(2006).
On the nature of cavities on protein surfaces: application to the identification of drug-binding sites.
|
| |
Proteins,
63,
892-906.
|
 |
|
|
|
|
 |
I.K.Lund,
H.S.Andersen,
L.F.Iversen,
O.H.Olsen,
K.B.Møller,
A.K.Pedersen,
Y.Ge,
D.D.Holsworth,
M.J.Newman,
F.U.Axe,
and
N.P.Møller
(2004).
Structure-based design of selective and potent inhibitors of protein-tyrosine phosphatase beta.
|
| |
J Biol Chem,
279,
24226-24235.
|
 |
|
|
|
|
 |
S.D.Taylor,
and
B.Hill
(2004).
Recent advances in protein tyrosine phosphatase 1B inhibitors.
|
| |
Expert Opin Investig Drugs,
13,
199-214.
|
 |
|
|
|
|
 |
J.P.Sun,
A.A.Fedorov,
S.Y.Lee,
X.L.Guo,
K.Shen,
D.S.Lawrence,
S.C.Almo,
and
Z.Y.Zhang
(2003).
Crystal structure of PTP1B complexed with a potent and selective bidentate inhibitor.
|
| |
J Biol Chem,
278,
12406-12414.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
Z.Y.Zhang,
and
S.Y.Lee
(2003).
PTP1B inhibitors as potential therapeutics in the treatment of type 2 diabetes and obesity.
|
| |
Expert Opin Investig Drugs,
12,
223-233.
|
 |
|
|
|
|
 |
L.F.Iversen,
K.B.Moller,
A.K.Pedersen,
G.H.Peters,
A.S.Petersen,
H.S.Andersen,
S.Branner,
S.B.Mortensen,
and
N.P.Moller
(2002).
Structure determination of T cell protein-tyrosine phosphatase.
|
| |
J Biol Chem,
277,
19982-19990.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
P.Kuhn,
K.Wilson,
M.G.Patch,
and
R.C.Stevens
(2002).
The genesis of high-throughput structure-based drug discovery using protein crystallography.
|
| |
Curr Opin Chem Biol,
6,
704-710.
|
 |
|
|
|
|
 |
S.F.Betz,
S.M.Baxter,
and
J.S.Fetrow
(2002).
Function first: a powerful approach to post-genomic drug discovery.
|
| |
Drug Discov Today,
7,
865-871.
|
 |
|
|
|
|
 |
T.O.Johnson,
J.Ermolieff,
and
M.R.Jirousek
(2002).
Protein tyrosine phosphatase 1B inhibitors for diabetes.
|
| |
Nat Rev Drug Discov,
1,
696-709.
|
 |
|
|
|
|
 |
X.L.Guo,
K.Shen,
F.Wang,
D.S.Lawrence,
and
Z.Y.Zhang
(2002).
Probing the molecular basis for potent and selective protein-tyrosine phosphatase 1B inhibition.
|
| |
J Biol Chem,
277,
41014-41022.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |